Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
This is precisely where StockStory comes in - our job is to find you high-quality companies that can win regardless of the conditions. Keeping that in mind, here are two large-cap stocks whose competitive advantages create flywheel effects and one whose existing offerings may be tapped out.
One large-cap stock to sell:
PACCAR (PCAR)
Market cap: $53.86 billion
Founded more than a century ago, PACCAR (NASDAQ: PCAR) designs and manufactures commercial trucks of various weights and sizes for the commercial trucking industry.
Why Are We Hesitant About PCAR?
- Customers postponed purchases of its products and services this cycle as its revenue declined by 8.6% annually over the last two years
- Falling earnings per share over the last two years has some investors worried as stock prices ultimately follow EPS over the long term
- Diminishing returns on capital suggest its earlier profit pools are drying up
At $104.49 per share, PACCAR trades at 15.7x forward P/E. Read our free research report to see why you should think twice about including PCAR in your portfolio.
Two large-cap stocks to buy:
Fastenal (FAST)
Market cap: $60.29 billion
Founded in 1967, Fastenal (NASDAQ: FAST) provides industrial and construction supplies, including fasteners, tools, safety products, and many other product categories to businesses globally.
Why Is FAST a Good Business?
- Superior product capabilities and pricing power lead to a best-in-class gross margin of 45.3%
- Highly efficient business model is illustrated by its impressive 20.5% operating margin
- Industry-leading 32.3% return on capital demonstrates management’s skill in finding high-return investments
Fastenal’s stock price of $53.98 implies a valuation ratio of 37.2x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Cencora (COR)
Market cap: $63.07 billion
Formerly known as AmerisourceBergen until its 2023 rebranding, Cencora (NYSE: COR) is a global pharmaceutical distribution company that connects manufacturers with healthcare providers while offering logistics, data analytics, and consulting services.
Why Are We Bullish on COR?
- Enormous revenue base of $332.8 billion gives it leverage over plan holders and advantageous reimbursement terms with healthcare providers
- Share buybacks catapulted its annual earnings per share growth to 14.4%, which outperformed its revenue gains over the last five years
- Stellar returns on capital showcase management’s ability to surface highly profitable business ventures
Cencora is trading at $327.88 per share, or 16.8x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.
Stocks we like even more
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
